Listen: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO
This week on "The Readout LOUD" podcast: When is a failure not a failure? Does the FDA have special rules for Sarepta Therapeutics? And how do you say "brash" in…
When is a failure not a failure? Does the FDA have special rules for Sarepta Therapeutics? And how do you say “brash” in French?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Biotech consultant Frank David joins us to explain the wild world of subgroup analyses and how to discern science from spin. We also discuss the latest news in the life sciences, including the future of Sarepta and the retirement of a biotech stalwart.
What's Your Reaction?
